speb/financial-data huggingface dataset:
DRUG income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 15845.00
DRUG cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -25620.00
DRUG income_statement (quarterly, 2025-06-30) — Research And Development: 2691854.00
DRUG balance_sheet (quarterly, 2025-06-30) — Retained Earnings: -42492714.00
DRUG income_statement (quarterly, 2025-06-30) — Salaries And Wages: 141757.00
DRUG income_statement (quarterly, 2025-06-30) — Selling And Marketing Expense: 112676.00
DRUG income_statement (quarterly, 2025-06-30) — Selling General And Administration: 591936.00
DRUG balance_sheet (quarterly, 2025-06-30) — Share Issued: 7084639.00
DRUG cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 1321372.00
DRUG balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 51829727.00
DRUG balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 51829727.00
DRUG income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 0.00
DRUG income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.00
DRUG balance_sheet (quarterly, 2025-06-30) — Taxes Receivable: 115168.00
DRUG balance_sheet (quarterly, 2025-06-30) — Total Assets: 52497560.00
DRUG balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 51829727.00
DRUG balance_sheet (quarterly, 2025-06-30) — Total Debt: 141030.00
DRUG balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 51829727.00
DRUG income_statement (quarterly, 2025-06-30) — Total Expenses: 3296310.00
DRUG balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 667833.00
DRUG balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 128976.00
DRUG balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 62842.00
DRUG income_statement (quarterly, 2025-06-30) — Total Unusual Items: -2680760.00
DRUG income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: -2680760.00
DRUG balance_sheet (quarterly, 2025-06-30) — Working Capital: 51763593.00
DRUG income_statement (annual, 2025-09-30) — +Operating Expense: 13937584.00
DRUG income_statement (quarterly, 2025-09-30) — +Operating Expense: 5664542.00
DRUG income_statement (annual, 2025-09-30) — +Total Revenue: 0.00
DRUG income_statement (quarterly, 2025-09-30) — +Total Revenue: 0.00
DRUG balance_sheet (annual, 2025-09-30) — Accounts Payable: 1710290.00
DRUG balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 1710290.00
DRUG balance_sheet (annual, 2025-09-30) — Accrued Interest Receivable: 203153.00
DRUG balance_sheet (quarterly, 2025-09-30) — Accrued Interest Receivable: 203153.00
DRUG income_statement (annual, 2025-09-30) — Basic Average Shares: 6878051.00
DRUG income_statement (annual, 2025-09-30) — Basic EPS: -1.78
DRUG cash_flow (annual, 2025-09-30) — Beginning Cash Position: 5720092.00
DRUG cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 51387560.00
DRUG balance_sheet (annual, 2025-09-30) — Capital Lease Obligations: 125777.00
DRUG balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 125777.00
DRUG balance_sheet (annual, 2025-09-30) — Capital Stock: 123249838.00
DRUG balance_sheet (quarterly, 2025-09-30) — Capital Stock: 123249838.00
DRUG balance_sheet (annual, 2025-09-30) — Cash And Cash Equivalents: 82908589.00
DRUG balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 82908589.00
DRUG balance_sheet (annual, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 82908589.00
DRUG balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 82908589.00
DRUG balance_sheet (annual, 2025-09-30) — Cash Equivalents: 86250.00
DRUG balance_sheet (quarterly, 2025-09-30) — Cash Equivalents: 86250.00
DRUG balance_sheet (annual, 2025-09-30) — Cash Financial: 82822339.00
DRUG balance_sheet (quarterly, 2025-09-30) — Cash Financial: 82822339.00
DRUG cash_flow (annual, 2025-09-30) — Cash Flow From Continuing Financing Activities: 85567491.00
DRUG cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: 33318073.00
DRUG cash_flow (annual, 2025-09-30) — Cash Flow From Continuing Operating Activities: -8691619.00
DRUG cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: -2958574.00
DRUG cash_flow (annual, 2025-09-30) — Change In Payables And Accrued Expense: 1689124.00
DRUG cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: 1611620.00
DRUG cash_flow (annual, 2025-09-30) — Change In Prepaid Assets: -771283.00
DRUG cash_flow (quarterly, 2025-09-30) — Change In Prepaid Assets: -279521.00
DRUG cash_flow (annual, 2025-09-30) — Change In Receivables: -362847.00
DRUG cash_flow (quarterly, 2025-09-30) — Change In Receivables: -140437.00
DRUG cash_flow (annual, 2025-09-30) — Change In Working Capital: 554994.00
DRUG cash_flow (quarterly, 2025-09-30) — Change In Working Capital: 1191662.00
DRUG cash_flow (annual, 2025-09-30) — Changes In Cash: 76875872.00
DRUG cash_flow (quarterly, 2025-09-30) — Changes In Cash: 32050065.00
DRUG balance_sheet (annual, 2025-09-30) — Common Stock: 123249838.00
DRUG balance_sheet (quarterly, 2025-09-30) — Common Stock: 123249838.00
DRUG balance_sheet (annual, 2025-09-30) — Common Stock Equity: 82044923.00
DRUG balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 82044923.00
DRUG cash_flow (annual, 2025-09-30) — Common Stock Issuance: 82097564.00
DRUG cash_flow (quarterly, 2025-09-30) — Common Stock Issuance: 33468600.00
DRUG balance_sheet (annual, 2025-09-30) — Current Accrued Expenses: 540549.00
DRUG balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 540549.00
DRUG balance_sheet (annual, 2025-09-30) — Current Assets: 84309571.00
DRUG balance_sheet (quarterly, 2025-09-30) — Current Assets: 84309571.00
DRUG balance_sheet (annual, 2025-09-30) — Current Capital Lease Obligation: 84528.00
DRUG balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 84528.00
DRUG balance_sheet (annual, 2025-09-30) — Current Debt And Capital Lease Obligation: 84528.00
DRUG balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 84528.00
DRUG balance_sheet (annual, 2025-09-30) — Current Liabilities: 2335367.00
DRUG balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 2335367.00
DRUG cash_flow (annual, 2025-09-30) — Depreciation: 76868.00
DRUG cash_flow (quarterly, 2025-09-30) — Depreciation: 17009.00
DRUG cash_flow (annual, 2025-09-30) — Depreciation Amortization Depletion: 76868.00
DRUG cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 17009.00
DRUG cash_flow (annual, 2025-09-30) — Depreciation And Amortization: 76868.00
DRUG cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 17009.00
DRUG income_statement (annual, 2025-09-30) — Diluted Average Shares: 6878051.00
DRUG income_statement (annual, 2025-09-30) — Diluted EPS: -1.78
DRUG income_statement (annual, 2025-09-30) — Diluted NI Availto Com Stockholders: -12229348.00
DRUG income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -4085603.00
DRUG income_statement (annual, 2025-09-30) — EBIT: -13937584.00
DRUG income_statement (quarterly, 2025-09-30) — EBIT: -5664542.00
DRUG income_statement (annual, 2025-09-30) — EBITDA: -13860716.00
DRUG income_statement (quarterly, 2025-09-30) — EBITDA: -5647533.00
DRUG cash_flow (annual, 2025-09-30) — Effect Of Exchange Rate Changes: 312625.00
DRUG cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: -529036.00
DRUG cash_flow (annual, 2025-09-30) — End Cash Position: 82908589.00
DRUG cash_flow (quarterly, 2025-09-30) — End Cash Position: 82908589.00
DRUG cash_flow (annual, 2025-09-30) — Financing Cash Flow: 85567491.00
DRUG cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: 33318073.00
DRUG cash_flow (annual, 2025-09-30) — Free Cash Flow: -8691619.00
DRUG cash_flow (quarterly, 2025-09-30) — Free Cash Flow: -1268008.00
DRUG income_statement (annual, 2025-09-30) — Gain On Sale Of Security: 188768.00
DRUG income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: 1307270.00
DRUG balance_sheet (annual, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 5373402.00
DRUG balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: 5373402.00
DRUG income_statement (annual, 2025-09-30) — General And Administrative Expense: 2135770.00
DRUG income_statement (quarterly, 2025-09-30) — General And Administrative Expense: 603962.00
DRUG balance_sheet (annual, 2025-09-30) — Gross PPE: 111968.00
DRUG balance_sheet (quarterly, 2025-09-30) — Gross PPE: 111968.00
DRUG income_statement (annual, 2025-09-30) — Interest Income: 1519468.00
DRUG income_statement (quarterly, 2025-09-30) — Interest Income: 529538.00
DRUG income_statement (annual, 2025-09-30) — Interest Income Non Operating: 1519468.00
DRUG income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 529538.00
DRUG balance_sheet (annual, 2025-09-30) — Invested Capital: 82044923.00
DRUG balance_sheet (quarterly, 2025-09-30) — Invested Capital: 82044923.00
DRUG cash_flow (annual, 2025-09-30) — Issuance Of Capital Stock: 82097564.00
DRUG cash_flow (quarterly, 2025-09-30) — Issuance Of Capital Stock: 33468600.00
DRUG balance_sheet (annual, 2025-09-30) — Leases: 111968.00
DRUG balance_sheet (quarterly, 2025-09-30) — Leases: 111968.00
DRUG balance_sheet (annual, 2025-09-30) — Long Term Capital Lease Obligation: 41249.00
DRUG balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 41249.00
DRUG balance_sheet (annual, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 41249.00
DRUG balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 41249.00
DRUG cash_flow (annual, 2025-09-30) — Long Term Debt Payments: -100150.00
DRUG cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: -26110.00
DRUG cash_flow (annual, 2025-09-30) — Net Common Stock Issuance: 82097564.00
DRUG cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: 33468600.00
DRUG cash_flow (annual, 2025-09-30) — Net Foreign Currency Exchange Gain Loss: -312687.00
DRUG cash_flow (quarterly, 2025-09-30) — Net Foreign Currency Exchange Gain Loss: -1157970.00
DRUG income_statement (annual, 2025-09-30) — Net Income: -12229348.00
DRUG income_statement (quarterly, 2025-09-30) — Net Income: -4085603.00
DRUG income_statement (annual, 2025-09-30) — Net Income Common Stockholders: -12229348.00
DRUG income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -4085603.00
DRUG income_statement (annual, 2025-09-30) — Net Income Continuous Operations: -12229348.00
DRUG income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -4085603.00
DRUG income_statement (annual, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -12229348.00
DRUG income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -4085603.00
DRUG income_statement (annual, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -12229348.00
DRUG income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -4085603.00
DRUG cash_flow (annual, 2025-09-30) — Net Income From Continuing Operations: -12229348.00
DRUG cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -4085603.00
DRUG income_statement (annual, 2025-09-30) — Net Income Including Noncontrolling Interests: -12229348.00
DRUG income_statement (quarterly, 2025-09-30) — Net Income Including Noncontrolling Interests: -4085603.00
DRUG income_statement (annual, 2025-09-30) — Net Interest Income: 1519468.00
DRUG income_statement (quarterly, 2025-09-30) — Net Interest Income: 529538.00
DRUG cash_flow (annual, 2025-09-30) — Net Issuance Payments Of Debt: -100150.00
DRUG cash_flow (quarterly, 2025-09-30) — Net Issuance Payments Of Debt: -26110.00
DRUG cash_flow (annual, 2025-09-30) — Net Long Term Debt Issuance: -100150.00
DRUG cash_flow (quarterly, 2025-09-30) — Net Long Term Debt Issuance: -26110.00
DRUG income_statement (annual, 2025-09-30) — Net Non Operating Interest Income Expense: 1519468.00
DRUG income_statement (quarterly, 2025-09-30) — Net Non Operating Interest Income Expense: 529538.00
DRUG cash_flow (annual, 2025-09-30) — Net Other Financing Charges: -360138.00
DRUG cash_flow (quarterly, 2025-09-30) — Net Other Financing Charges: -276418.00
DRUG balance_sheet (annual, 2025-09-30) — Net PPE: 111968.00
DRUG balance_sheet (quarterly, 2025-09-30) — Net PPE: 111968.00
DRUG balance_sheet (annual, 2025-09-30) — Net Tangible Assets: 82044923.00
DRUG balance_sheet (quarterly, 2025-09-30) — Net Tangible Assets: 82044923.00
DRUG income_statement (annual, 2025-09-30) — Normalized EBITDA: -14049484.00
DRUG income_statement (quarterly, 2025-09-30) — Normalized EBITDA: -6954803.00
DRUG income_statement (annual, 2025-09-30) — Normalized Income: -12418116.00
DRUG income_statement (quarterly, 2025-09-30) — Normalized Income: -5392873.00
DRUG cash_flow (annual, 2025-09-30) — Operating Cash Flow: -8691619.00
DRUG cash_flow (quarterly, 2025-09-30) — Operating Cash Flow: -1268008.00
DRUG cash_flow (annual, 2025-09-30) — Operating Gains Losses: -312687.00
DRUG cash_flow (quarterly, 2025-09-30) — Operating Gains Losses: -1157970.00
DRUG income_statement (annual, 2025-09-30) — Operating Income: -13937584.00
DRUG income_statement (quarterly, 2025-09-30) — Operating Income: -5664542.00
DRUG income_statement (annual, 2025-09-30) — Operating Revenue: 0.00
DRUG income_statement (quarterly, 2025-09-30) — Operating Revenue: 0.00
DRUG balance_sheet (annual, 2025-09-30) — Ordinary Shares Number: 7635789.00
DRUG balance_sheet (quarterly, 2025-09-30) — Ordinary Shares Number: 7635789.00
DRUG income_statement (annual, 2025-09-30) — Other Gand A: 1638464.00
DRUG income_statement (quarterly, 2025-09-30) — Other Gand A: 436761.00
DRUG income_statement (annual, 2025-09-30) — Other Income Expense: 188768.00
DRUG income_statement (quarterly, 2025-09-30) — Other Income Expense: 1049401.00
DRUG cash_flow (annual, 2025-09-30) — Other Non Cash Items: 35851.00
DRUG cash_flow (quarterly, 2025-09-30) — Other Non Cash Items: 1697862.00
DRUG income_statement (annual, 2025-09-30) — Other Operating Expenses: 287646.00
DRUG income_statement (quarterly, 2025-09-30) — Other Operating Expenses: 123932.00
DRUG balance_sheet (annual, 2025-09-30) — Payables: 1710290.00
DRUG balance_sheet (quarterly, 2025-09-30) — Payables: 1710290.00
DRUG balance_sheet (annual, 2025-09-30) — Payables And Accrued Expenses: 2250839.00
DRUG balance_sheet (quarterly, 2025-09-30) — Payables And Accrued Expenses: 2250839.00
DRUG balance_sheet (annual, 2025-09-30) — Prepaid Assets: 987911.00
DRUG balance_sheet (quarterly, 2025-09-30) — Prepaid Assets: 987911.00
DRUG income_statement (annual, 2025-09-30) — Pretax Income: -12229348.00
DRUG income_statement (quarterly, 2025-09-30) — Pretax Income: -4085603.00
DRUG cash_flow (annual, 2025-09-30) — Proceeds From Stock Option Exercised: 3930215.00
DRUG cash_flow (quarterly, 2025-09-30) — Proceeds From Stock Option Exercised: 152001.00
DRUG balance_sheet (annual, 2025-09-30) — Properties: 0.00
DRUG balance_sheet (quarterly, 2025-09-30) — Properties: 0.00
DRUG balance_sheet (annual, 2025-09-30) — Receivables: 413071.00
DRUG balance_sheet (quarterly, 2025-09-30) — Receivables: 413071.00
DRUG income_statement (annual, 2025-09-30) — Reconciled Depreciation: 76868.00
DRUG income_statement (quarterly, 2025-09-30) — Reconciled Depreciation: 17009.00
DRUG cash_flow (annual, 2025-09-30) — Repayment Of Debt: -100150.00
DRUG cash_flow (quarterly, 2025-09-30) — Repayment Of Debt: -26110.00
DRUG income_statement (annual, 2025-09-30) — Research And Development: 11084509.00
DRUG income_statement (quarterly, 2025-09-30) — Research And Development: 4784205.00
DRUG balance_sheet (annual, 2025-09-30) — Retained Earnings: -46578317.00
DRUG balance_sheet (quarterly, 2025-09-30) — Retained Earnings: -46578317.00
DRUG income_statement (annual, 2025-09-30) — Salaries And Wages: 497306.00
DRUG income_statement (quarterly, 2025-09-30) — Salaries And Wages: 167201.00
DRUG income_statement (annual, 2025-09-30) — Selling And Marketing Expense: 429659.00
DRUG income_statement (quarterly, 2025-09-30) — Selling And Marketing Expense: 152443.00
DRUG income_statement (annual, 2025-09-30) — Selling General And Administration: 2565429.00
DRUG income_statement (quarterly, 2025-09-30) — Selling General And Administration: 756405.00
DRUG balance_sheet (annual, 2025-09-30) — Share Issued: 7635789.00
DRUG balance_sheet (quarterly, 2025-09-30) — Share Issued: 7635789.00
DRUG cash_flow (annual, 2025-09-30) — Stock Based Compensation: 3182703.00
DRUG cash_flow (quarterly, 2025-09-30) — Stock Based Compensation: 1069032.00
DRUG balance_sheet (annual, 2025-09-30) — Stockholders Equity: 82044923.00
DRUG balance_sheet (quarterly, 2025-09-30) — Stockholders Equity: 82044923.00
DRUG balance_sheet (annual, 2025-09-30) — Tangible Book Value: 82044923.00
DRUG balance_sheet (quarterly, 2025-09-30) — Tangible Book Value: 82044923.00
DRUG income_statement (annual, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
DRUG income_statement (quarterly, 2025-09-30) — Tax Effect Of Unusual Items: 0.00
DRUG income_statement (annual, 2025-09-30) — Tax Rate For Calcs: 0.00
DRUG income_statement (quarterly, 2025-09-30) — Tax Rate For Calcs: 0.00
DRUG balance_sheet (annual, 2025-09-30) — Taxes Receivable: 209918.00
DRUG balance_sheet (quarterly, 2025-09-30) — Taxes Receivable: 209918.00
DRUG balance_sheet (annual, 2025-09-30) — Total Assets: 84421539.00
DRUG balance_sheet (quarterly, 2025-09-30) — Total Assets: 84421539.00
DRUG balance_sheet (annual, 2025-09-30) — Total Capitalization: 82044923.00
DRUG balance_sheet (quarterly, 2025-09-30) — Total Capitalization: 82044923.00
DRUG balance_sheet (annual, 2025-09-30) — Total Debt: 125777.00
DRUG balance_sheet (quarterly, 2025-09-30) — Total Debt: 125777.00
DRUG balance_sheet (annual, 2025-09-30) — Total Equity Gross Minority Interest: 82044923.00
DRUG balance_sheet (quarterly, 2025-09-30) — Total Equity Gross Minority Interest: 82044923.00
DRUG income_statement (annual, 2025-09-30) — Total Expenses: 13937584.00
DRUG income_statement (quarterly, 2025-09-30) — Total Expenses: 5664542.00
DRUG balance_sheet (annual, 2025-09-30) — Total Liabilities Net Minority Interest: 2376616.00
DRUG balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 2376616.00
DRUG balance_sheet (annual, 2025-09-30) — Total Non Current Assets: 111968.00
DRUG balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 111968.00
DRUG balance_sheet (annual, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 41249.00
DRUG balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 41249.00
DRUG income_statement (annual, 2025-09-30) — Total Unusual Items: 188768.00
DRUG income_statement (quarterly, 2025-09-30) — Total Unusual Items: 1307270.00
DRUG income_statement (annual, 2025-09-30) — Total Unusual Items Excluding Goodwill: 188768.00
DRUG income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: 1307270.00
DRUG balance_sheet (annual, 2025-09-30) — Working Capital: 81974204.00
DRUG balance_sheet (quarterly, 2025-09-30) — Working Capital: 81974204.00
DRUG income_statement (quarterly, 2025-12-31) — +Operating Expense: 6904082.00
DRUG income_statement (quarterly, 2025-12-31) — +Total Revenue: 0.00
DRUG balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 1431404.00
DRUG balance_sheet (quarterly, 2025-12-31) — Accrued Interest Receivable: 262198.00
DRUG income_statement (quarterly, 2025-12-31) — Basic Average Shares: 7761288.00
DRUG income_statement (quarterly, 2025-12-31) — Basic EPS: -0.97
DRUG cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 82908589.00
DRUG balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 104900.00
DRUG balance_sheet (quarterly, 2025-12-31) — Capital Stock: 136772060.00
DRUG balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 89047867.00
DRUG balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 89047867.00
DRUG balance_sheet (quarterly, 2025-12-31) — Cash Equivalents: 172500.00
DRUG balance_sheet (quarterly, 2025-12-31) — Cash Financial: 88875367.00
DRUG cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 13390841.00
DRUG cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: -5815901.00
DRUG cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: -906764.00
DRUG cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: -59045.00
DRUG cash_flow (quarterly, 2025-12-31) — Change In Receivables: -30564.00
DRUG cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -996373.00
DRUG cash_flow (quarterly, 2025-12-31) — Changes In Cash: 7574940.00
DRUG balance_sheet (quarterly, 2025-12-31) — Common Stock: 136772060.00
DRUG balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 89280549.00
DRUG cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 13944237.00
DRUG balance_sheet (quarterly, 2025-12-31) — Current Accrued Expenses: 63000.00
DRUG balance_sheet (quarterly, 2025-12-31) — Current Assets: 90787674.00
DRUG balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 88156.00
DRUG balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 88156.00
DRUG balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 1582560.00
DRUG cash_flow (quarterly, 2025-12-31) — Depreciation: 19789.00
DRUG cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 19789.00
DRUG cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 19789.00
DRUG income_statement (quarterly, 2025-12-31) — Diluted Average Shares: 7761288.00
DRUG income_statement (quarterly, 2025-12-31) — Diluted EPS: -0.97
DRUG income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: -7565318.00
DRUG income_statement (quarterly, 2025-12-31) — EBIT: -6904082.00
DRUG income_statement (quarterly, 2025-12-31) — EBITDA: -6884293.00
DRUG cash_flow (quarterly, 2025-12-31) — Effect Of Exchange Rate Changes: -1435662.00
DRUG cash_flow (quarterly, 2025-12-31) — End Cash Position: 89047867.00
DRUG cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 13390841.00
DRUG cash_flow (quarterly, 2025-12-31) — Free Cash Flow: -5815901.00
DRUG income_statement (quarterly, 2025-12-31) — Gain On Sale Of Security: -1479501.00
DRUG balance_sheet (quarterly, 2025-12-31) — Gains Losses Not Affecting Retained Earnings: 6652124.00
DRUG income_statement (quarterly, 2025-12-31) — General And Administrative Expense: 990110.00
DRUG balance_sheet (quarterly, 2025-12-31) — Gross PPE: 92179.00
DRUG income_statement (quarterly, 2025-12-31) — Interest Income: 818265.00
DRUG income_statement (quarterly, 2025-12-31) — Interest Income Non Operating: 818265.00
DRUG balance_sheet (quarterly, 2025-12-31) — Invested Capital: 89280549.00
DRUG cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 13944237.00
DRUG balance_sheet (quarterly, 2025-12-31) — Leases: 92179.00
DRUG balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 16744.00
DRUG balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 16744.00
DRUG cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: -26025.00
DRUG cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 13944237.00
DRUG cash_flow (quarterly, 2025-12-31) — Net Foreign Currency Exchange Gain Loss: 1434232.00
DRUG income_statement (quarterly, 2025-12-31) — Net Income: -7565318.00
DRUG income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: -7565318.00
DRUG income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: -7565318.00
DRUG income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -7565318.00
DRUG income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -7565318.00
DRUG cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: -7565318.00
DRUG income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: -7565318.00
DRUG income_statement (quarterly, 2025-12-31) — Net Interest Income: 818265.00
DRUG cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: -26025.00
DRUG cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: -26025.00
DRUG income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: 818265.00
DRUG cash_flow (quarterly, 2025-12-31) — Net Other Financing Charges: -536121.00
DRUG balance_sheet (quarterly, 2025-12-31) — Net PPE: 92179.00
DRUG balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 89280549.00
DRUG income_statement (quarterly, 2025-12-31) — Normalized EBITDA: -5404792.00
DRUG income_statement (quarterly, 2025-12-31) — Normalized Income: -6085817.00
DRUG cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: -5815901.00
DRUG cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: 1434232.00
DRUG income_statement (quarterly, 2025-12-31) — Operating Income: -6904082.00
DRUG income_statement (quarterly, 2025-12-31) — Operating Revenue: 0.00
DRUG balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 7787161.00
DRUG income_statement (quarterly, 2025-12-31) — Other Gand A: 770185.00
DRUG income_statement (quarterly, 2025-12-31) — Other Income Expense: -1479501.00
DRUG cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 6578.00
DRUG income_statement (quarterly, 2025-12-31) — Other Operating Expenses: 154215.00
DRUG balance_sheet (quarterly, 2025-12-31) — Payables: 1431404.00
DRUG balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 1494404.00
DRUG balance_sheet (quarterly, 2025-12-31) — Prepaid Assets: 1237127.00
DRUG income_statement (quarterly, 2025-12-31) — Pretax Income: -7565318.00
DRUG cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 8750.00
DRUG balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
DRUG balance_sheet (quarterly, 2025-12-31) — Receivables: 502680.00
DRUG income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 19789.00
DRUG cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: -26025.00
DRUG income_statement (quarterly, 2025-12-31) — Research And Development: 5660654.00
DRUG balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -54143635.00
DRUG income_statement (quarterly, 2025-12-31) — Salaries And Wages: 219925.00
DRUG income_statement (quarterly, 2025-12-31) — Selling And Marketing Expense: 99103.00
DRUG income_statement (quarterly, 2025-12-31) — Selling General And Administration: 1089213.00
DRUG balance_sheet (quarterly, 2025-12-31) — Share Issued: 7787161.00
DRUG cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 1285191.00
DRUG balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 89280549.00
DRUG balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: 89280549.00
DRUG income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: 0.00
DRUG income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.00
DRUG balance_sheet (quarterly, 2025-12-31) — Taxes Receivable: 240482.00
DRUG balance_sheet (quarterly, 2025-12-31) — Total Assets: 90879853.00
DRUG balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 89280549.00
DRUG balance_sheet (quarterly, 2025-12-31) — Total Debt: 104900.00
DRUG balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 89280549.00
DRUG income_statement (quarterly, 2025-12-31) — Total Expenses: 6904082.00
DRUG balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 1599304.00
DRUG balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 92179.00
DRUG balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 16744.00
DRUG income_statement (quarterly, 2025-12-31) — Total Unusual Items: -1479501.00
DRUG income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -1479501.00
DRUG balance_sheet (quarterly, 2025-12-31) — Working Capital: 89205114.00
DRUG income_statement (quarterly, 2026-03-31) — +Operating Expense: 15319423.00
DRUG income_statement (quarterly, 2026-03-31) — +Total Revenue: 0.00
DRUG balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 3629907.00
DRUG balance_sheet (quarterly, 2026-03-31) — Accrued Interest Receivable: 979600.00
DRUG income_statement (quarterly, 2026-03-31) — Basic Average Shares: 9589842.00
DRUG income_statement (quarterly, 2026-03-31) — Basic EPS: -1.09
DRUG cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 89047867.00
DRUG balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 82130.00
DRUG balance_sheet (quarterly, 2026-03-31) — Capital Stock: 365779008.00
DRUG balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 309691863.00
DRUG balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 309691863.00
DRUG balance_sheet (quarterly, 2026-03-31) — Cash Equivalents: 172500.00
DRUG balance_sheet (quarterly, 2026-03-31) — Cash Financial: 309519363.00
DRUG cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 228466733.00
DRUG cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -9246100.00
DRUG cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: 2518898.00
DRUG cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -414003.00
DRUG cash_flow (quarterly, 2026-03-31) — Change In Receivables: -696276.00
DRUG cash_flow (quarterly, 2026-03-31) — Change In Working Capital: 1408619.00
DRUG cash_flow (quarterly, 2026-03-31) — Changes In Cash: 219220633.00
DRUG balance_sheet (quarterly, 2026-03-31) — Common Stock: 365779008.00
DRUG balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 308532424.00
DRUG cash_flow (quarterly, 2026-03-31) — Common Stock Issuance: 243249480.00
DRUG balance_sheet (quarterly, 2026-03-31) — Current Accrued Expenses: 120650.00
DRUG balance_sheet (quarterly, 2026-03-31) — Current Assets: 312292733.00
DRUG balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 82130.00
DRUG balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 82130.00
DRUG balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 3832687.00
DRUG cash_flow (quarterly, 2026-03-31) — Depreciation: 19801.00
DRUG cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 19801.00
DRUG cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 19801.00
DRUG income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 9589842.00
DRUG income_statement (quarterly, 2026-03-31) — Diluted EPS: -1.09
DRUG income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -10459627.00
DRUG income_statement (quarterly, 2026-03-31) — EBIT: -15319423.00
DRUG income_statement (quarterly, 2026-03-31) — EBITDA: -15299622.00
DRUG cash_flow (quarterly, 2026-03-31) — Effect Of Exchange Rate Changes: 1423363.00
DRUG cash_flow (quarterly, 2026-03-31) — End Cash Position: 309691863.00
DRUG cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 228466733.00
DRUG cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -9246100.00
DRUG income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: 2169876.00
DRUG balance_sheet (quarterly, 2026-03-31) — Gains Losses Not Affecting Retained Earnings: 7356678.00
DRUG income_statement (quarterly, 2026-03-31) — General And Administrative Expense: 2127115.00
DRUG balance_sheet (quarterly, 2026-03-31) — Gross PPE: 72378.00
DRUG income_statement (quarterly, 2026-03-31) — Interest Income: 2689920.00
DRUG income_statement (quarterly, 2026-03-31) — Interest Income Non Operating: 2689920.00
DRUG balance_sheet (quarterly, 2026-03-31) — Invested Capital: 308532424.00
DRUG cash_flow (quarterly, 2026-03-31) — Issuance Of Capital Stock: 243249480.00
DRUG balance_sheet (quarterly, 2026-03-31) — Leases: 72378.00
DRUG balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 0.00
DRUG balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 0.00
DRUG cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -26268.00
DRUG cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: 243249480.00
DRUG cash_flow (quarterly, 2026-03-31) — Net Foreign Currency Exchange Gain Loss: -1425366.00
DRUG income_statement (quarterly, 2026-03-31) — Net Income: -10459627.00
DRUG income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -10459627.00
DRUG income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -10459627.00
DRUG income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -10459627.00
DRUG income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -10459627.00
DRUG cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -10459627.00
DRUG income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -10459627.00
DRUG income_statement (quarterly, 2026-03-31) — Net Interest Income: 2689920.00
DRUG cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: -26268.00
DRUG cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: -26268.00
DRUG income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: 2689920.00
DRUG cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -14799067.00
DRUG balance_sheet (quarterly, 2026-03-31) — Net PPE: 72378.00
DRUG balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 308532424.00
DRUG income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -17469498.00
DRUG income_statement (quarterly, 2026-03-31) — Normalized Income: -12629503.00
DRUG cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -9246100.00
DRUG cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: -1425366.00
DRUG income_statement (quarterly, 2026-03-31) — Operating Income: -15319423.00
DRUG income_statement (quarterly, 2026-03-31) — Operating Revenue: 0.00
DRUG balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 9812061.00
DRUG income_statement (quarterly, 2026-03-31) — Other Gand A: 1870665.00
DRUG income_statement (quarterly, 2026-03-31) — Other Income Expense: 2169876.00
DRUG cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 5501.00
DRUG income_statement (quarterly, 2026-03-31) — Other Operating Expenses: 42483.00
DRUG balance_sheet (quarterly, 2026-03-31) — Payables: 3629907.00
DRUG balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 3750557.00
DRUG balance_sheet (quarterly, 2026-03-31) — Prepaid Assets: 1460959.00
DRUG income_statement (quarterly, 2026-03-31) — Pretax Income: -10459627.00
DRUG cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 42588.00
DRUG balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
DRUG balance_sheet (quarterly, 2026-03-31) — Receivables: 1139911.00
DRUG income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 19801.00
DRUG cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -26268.00
DRUG income_statement (quarterly, 2026-03-31) — Research And Development: 13047694.00
DRUG balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -64603262.00
DRUG income_statement (quarterly, 2026-03-31) — Salaries And Wages: 256450.00
DRUG income_statement (quarterly, 2026-03-31) — Selling And Marketing Expense: 102131.00
DRUG income_statement (quarterly, 2026-03-31) — Selling General And Administration: 2229246.00
DRUG balance_sheet (quarterly, 2026-03-31) — Share Issued: 9812061.00
DRUG cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 1204972.00
DRUG balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 308532424.00
DRUG balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 308532424.00
DRUG income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
DRUG income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.00
DRUG balance_sheet (quarterly, 2026-03-31) — Taxes Receivable: 160311.00
DRUG balance_sheet (quarterly, 2026-03-31) — Total Assets: 312365111.00
DRUG balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 308532424.00
DRUG balance_sheet (quarterly, 2026-03-31) — Total Debt: 82130.00
DRUG balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 308532424.00
DRUG income_statement (quarterly, 2026-03-31) — Total Expenses: 15319423.00
DRUG balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 3832687.00
DRUG balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 72378.00
DRUG balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 0.00
DRUG income_statement (quarterly, 2026-03-31) — Total Unusual Items: 2169876.00
DRUG income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: 2169876.00
DRUG balance_sheet (quarterly, 2026-03-31) — Working Capital: 308460046.00
DRVN cash_flow (annual, 2021-12-31) — Amortization Of Securities: 0.00
DRVN income_statement (annual, 2021-12-31) — Average Dilution Earnings: 22000.00
DRVN cash_flow (annual, 2021-12-31) — Cash Dividends Paid: 0.00
DRVN cash_flow (annual, 2021-12-31) — Change In Other Current Liabilities: -60323000.00
DRVN cash_flow (annual, 2021-12-31) — Common Stock Issuance: 760725000.00
DRVN cash_flow (annual, 2021-12-31) — Gain Loss On Sale Of PPE: -11353000.00
DRVN income_statement (annual, 2021-12-31) — Impairment Of Capital Assets: 0.00
DRVN cash_flow (annual, 2021-12-31) — Income Tax Paid Supplemental Data: 12764000.00
DRVN cash_flow (annual, 2021-12-31) — Interest Paid Supplemental Data: 75807000.00
DRVN cash_flow (annual, 2021-12-31) — Issuance Of Capital Stock: 760725000.00
DRVN balance_sheet (annual, 2021-12-31) — Minority Interest: 1099000.00
DRVN income_statement (annual, 2021-12-31) — Minority Interests: 96000.00
DRVN cash_flow (annual, 2021-12-31) — Net Other Investing Changes: 144134000.00
DRVN cash_flow (annual, 2021-12-31) — Net Short Term Debt Issuance: -18000000.00
DRVN balance_sheet (annual, 2021-12-31) — Non Current Accrued Expenses: 29398000.00
DRVN balance_sheet (annual, 2021-12-31) — Non Current Note Receivables: 3182000.00
DRVN balance_sheet (annual, 2021-12-31) — Other Non Current Liabilities: 29398000.00
DRVN income_statement (annual, 2021-12-31) — Other Operating Expenses: 2497000.00
DRVN income_statement (annual, 2021-12-31) — Other Special Charges: 45576000.00
DRVN balance_sheet (annual, 2021-12-31) — Prepaid Assets: 24326000.00
DRVN income_statement (annual, 2021-12-31) — Restructuring And Mergern Acquisition: 62386000.00
DRVN cash_flow (annual, 2021-12-31) — Short Term Debt Issuance: 526800000.00
DRVN cash_flow (annual, 2021-12-31) — Short Term Debt Payments: -544800000.00
DRVN income_statement (annual, 2022-12-31) — +Operating Expense: 636802000.00
DRVN income_statement (annual, 2022-12-31) — +Total Revenue: 2033194000.00
DRVN balance_sheet (annual, 2022-12-31) — Accounts Payable: 60606000.00
DRVN balance_sheet (annual, 2022-12-31) — Accounts Receivable: 179888000.00
DRVN balance_sheet (annual, 2022-12-31) — Accumulated Depreciation: -256786000.00
DRVN balance_sheet (annual, 2022-12-31) — Additional Paid In Capital: 1628904000.00
DRVN balance_sheet (annual, 2022-12-31) — Allowance For Doubtful Accounts Receivable: -19606000.00
DRVN cash_flow (annual, 2022-12-31) — Amortization Cash Flow: 0.00
DRVN cash_flow (annual, 2022-12-31) — Amortization Of Intangibles: 0.00
DRVN cash_flow (annual, 2022-12-31) — Amortization Of Securities: -542000.00
DRVN cash_flow (annual, 2022-12-31) — Asset Impairment Charge: 136882000.00
DRVN balance_sheet (annual, 2022-12-31) — Assets Held For Sale Current: 0.00
DRVN income_statement (annual, 2022-12-31) — Average Dilution Earnings: 98000.00
DRVN income_statement (annual, 2022-12-31) — Basic Average Shares: 162762000.00
DRVN income_statement (annual, 2022-12-31) — Basic EPS: 0.26
DRVN cash_flow (annual, 2022-12-31) — Beginning Cash Position: 562792000.00
DRVN balance_sheet (annual, 2022-12-31) — Buildings And Improvements: 641520000.00
DRVN cash_flow (annual, 2022-12-31) — Capital Expenditure: -436205000.00
DRVN cash_flow (annual, 2022-12-31) — Capital Expenditure Reported: -436205000.00
DRVN balance_sheet (annual, 2022-12-31) — Capital Lease Obligations: 1177501000.00
DRVN balance_sheet (annual, 2022-12-31) — Capital Stock: 1674000.00
DRVN balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 227110000.00
DRVN balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 227110000.00
DRVN cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: 343368000.00
DRVN cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -840280000.00
DRVN cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Operating Activities: 197176000.00
DRVN cash_flow (annual, 2022-12-31) — Change In Account Payable: -34634000.00
DRVN cash_flow (annual, 2022-12-31) — Change In Accrued Expense: 2898000.00
DRVN cash_flow (annual, 2022-12-31) — Change In Inventory: -22712000.00
DRVN cash_flow (annual, 2022-12-31) — Change In Other Current Assets: -23378000.00
DRVN cash_flow (annual, 2022-12-31) — Change In Other Working Capital: 18030000.00
DRVN cash_flow (annual, 2022-12-31) — Change In Payable: -34634000.00
DRVN cash_flow (annual, 2022-12-31) — Change In Payables And Accrued Expense: -31736000.00
DRVN cash_flow (annual, 2022-12-31) — Change In Prepaid Assets: -30418000.00
DRVN cash_flow (annual, 2022-12-31) — Change In Receivables: -71172000.00
DRVN cash_flow (annual, 2022-12-31) — Change In Working Capital: -161386000.00
DRVN cash_flow (annual, 2022-12-31) — Changes In Account Receivables: -58837000.00
DRVN cash_flow (annual, 2022-12-31) — Changes In Cash: -299736000.00
DRVN balance_sheet (annual, 2022-12-31) — Common Stock: 1674000.00
DRVN balance_sheet (annual, 2022-12-31) — Common Stock Equity: 1652938000.00
DRVN cash_flow (annual, 2022-12-31) — Common Stock Issuance: 0.00
DRVN cash_flow (annual, 2022-12-31) — Common Stock Payments: 0.00
DRVN balance_sheet (annual, 2022-12-31) — Construction In Progress: 313821000.00
DRVN income_statement (annual, 2022-12-31) — Cost Of Revenue: 1065683000.00
DRVN balance_sheet (annual, 2022-12-31) — Current Accrued Expenses: 317318000.00
DRVN balance_sheet (annual, 2022-12-31) — Current Assets: 571410000.00
DRVN balance_sheet (annual, 2022-12-31) — Current Debt: 32986000.00
DRVN balance_sheet (annual, 2022-12-31) — Current Debt And Capital Lease Obligation: 32986000.00
DRVN balance_sheet (annual, 2022-12-31) — Current Liabilities: 505418000.00
DRVN cash_flow (annual, 2022-12-31) — Deferred Income Tax: 20567000.00
DRVN cash_flow (annual, 2022-12-31) — Deferred Tax: 20567000.00
DRVN cash_flow (annual, 2022-12-31) — Depreciation: 147156000.00
DRVN cash_flow (annual, 2022-12-31) — Depreciation Amortization Depletion: 147156000.00
DRVN income_statement (annual, 2022-12-31) — Depreciation Amortization Depletion Income Statement: 147156000.00
DRVN cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 147156000.00
DRVN income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 147156000.00
DRVN income_statement (annual, 2022-12-31) — Diluted Average Shares: 166743000.00
DRVN income_statement (annual, 2022-12-31) — Diluted EPS: 0.25
DRVN income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: 42274000.00
DRVN income_statement (annual, 2022-12-31) — EBIT: 182436000.00
DRVN income_statement (annual, 2022-12-31) — EBITDA: 329592000.00
DRVN cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: -2283000.00
DRVN cash_flow (annual, 2022-12-31) — End Cash Position: 260773000.00
DRVN cash_flow (annual, 2022-12-31) — Financing Cash Flow: 343368000.00
DRVN cash_flow (annual, 2022-12-31) — Free Cash Flow: -239029000.00
DRVN cash_flow (annual, 2022-12-31) — Gain Loss On Investment Securities: -521000.00
DRVN cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of Business: -34854000.00
DRVN cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of PPE: -34854000.00
DRVN income_statement (annual, 2022-12-31) — Gain On Sale Of Security: -17168000.00
DRVN balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: -62435000.00
DRVN income_statement (annual, 2022-12-31) — General And Administrative Expense: 401660000.00
DRVN balance_sheet (annual, 2022-12-31) — Goodwill: 2277065000.00
DRVN balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 3042968000.00
DRVN balance_sheet (annual, 2022-12-31) — Gross Accounts Receivable: 199494000.00
DRVN balance_sheet (annual, 2022-12-31) — Gross PPE: 3101713000.00
DRVN income_statement (annual, 2022-12-31) — Gross Profit: 967511000.00
DRVN income_statement (annual, 2022-12-31) — Impairment Of Capital Assets: 0.00
DRVN cash_flow (annual, 2022-12-31) — Income Tax Paid Supplemental Data: 17220000.00
DRVN balance_sheet (annual, 2022-12-31) — Income Tax Payable: 57782000.00
DRVN income_statement (annual, 2022-12-31) — Interest Expense: 114096000.00
DRVN income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 114096000.00
DRVN cash_flow (annual, 2022-12-31) — Interest Paid Supplemental Data: 113226000.00
DRVN balance_sheet (annual, 2022-12-31) — Inventory: 72040000.00
DRVN balance_sheet (annual, 2022-12-31) — Invested Capital: 4391205000.00
DRVN cash_flow (annual, 2022-12-31) — Investing Cash Flow: -840280000.00
DRVN cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 0.00
DRVN cash_flow (annual, 2022-12-31) — Issuance Of Debt: 800000000.00
DRVN balance_sheet (annual, 2022-12-31) — Land And Improvements: 127613000.00
DRVN balance_sheet (annual, 2022-12-31) — Leases: 228006000.00
DRVN balance_sheet (annual, 2022-12-31) — Long Term Capital Lease Obligation: 1177501000.00
DRVN balance_sheet (annual, 2022-12-31) — Long Term Debt: 2705281000.00
DRVN balance_sheet (annual, 2022-12-31) — Long Term Debt And Capital Lease Obligation: 3882782000.00
DRVN cash_flow (annual, 2022-12-31) — Long Term Debt Issuance: 800000000.00
DRVN cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -462281000.00
DRVN balance_sheet (annual, 2022-12-31) — Machinery Furniture Equipment: 72985000.00
DRVN balance_sheet (annual, 2022-12-31) — Minority Interest: 631000.00
DRVN income_statement (annual, 2022-12-31) — Minority Interests: 15000.00
DRVN cash_flow (annual, 2022-12-31) — Net Business Purchase And Sale: -737873000.00
DRVN cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 0.00
DRVN balance_sheet (annual, 2022-12-31) — Net Debt: 2511157000.00
DRVN cash_flow (annual, 2022-12-31) — Net Foreign Currency Exchange Gain Loss: 17147000.00
DRVN income_statement (annual, 2022-12-31) — Net Income: 43188000.00
DRVN income_statement (annual, 2022-12-31) — Net Income Common Stockholders: 42274000.00
DRVN income_statement (annual, 2022-12-31) — Net Income Continuous Operations: 43173000.00
DRVN income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: 43188000.00
DRVN income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: 43188000.00
DRVN cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: 43173000.00
DRVN income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: 43173000.00
DRVN income_statement (annual, 2022-12-31) — Net Interest Income: -114096000.00
DRVN cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: 337719000.00
DRVN cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: 337719000.00
DRVN income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -114096000.00
DRVN cash_flow (annual, 2022-12-31) — Net Other Financing Charges: 5309000.00
DRVN balance_sheet (annual, 2022-12-31) — Net PPE: 2844927000.00
DRVN cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: 333798000.00
DRVN cash_flow (annual, 2022-12-31) — Net Short Term Debt Issuance: 0.00
DRVN balance_sheet (annual, 2022-12-31) — Net Tangible Assets: -1390030000.00
DRVN balance_sheet (annual, 2022-12-31) — Non Current Accrued Expenses: 33419000.00
DRVN balance_sheet (annual, 2022-12-31) — Non Current Deferred Assets: 10032000.00
DRVN balance_sheet (annual, 2022-12-31) — Non Current Deferred Liabilities: 306795000.00
DRVN balance_sheet (annual, 2022-12-31) — Non Current Deferred Revenue: 30046000.00
DRVN balance_sheet (annual, 2022-12-31) — Non Current Deferred Taxes Assets: 2911000.00